As of Jun 27, 2018 Viking Therapeutics Inc (NASDAQ:VKTX) Shorts Declined By 0.3%

June 27, 2018 - By Catherine Smith

Viking Therapeutics, Inc. (NASDAQ:VKTX) Corporate Logo

Viking Therapeutics Inc (NASDAQ:VKTX) noted a decrease of 0.3% in short interest. In June was announced VKTX’s total 2.91M short interest by FINRA. The 2.92M previous shares are down with 0.3%. Viking Therapeutics Inc (NASDAQ:VKTX) has 892,100 shares average volume. It’ll cost 3 days for VKTX to restore its previous position. Viking Therapeutics Inc float short is 15.78%.

The stock decreased 0.58% or $0.06 during the last trading session, hitting $10.35.Viking Therapeutics, Inc. has volume of 1.30 million shares. Since June 27, 2017 VKTX has risen 320.16% and is uptrending. VKTX outperformed the S&P500 by 307.59%.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders.The company has $616.43 million market cap. The Company’s lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery.Currently it has negative earnings. The firm also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Ratings Coverage

A total of 4 analysts rate Viking Therapeutics (NASDAQ:VKTX) as follows: 4 “Buy”, 0 “Hold” and 0 “Sell”. Š¢herefore 100% are bullish. (NASDAQ:VKTX) has 5 ratings reports on Jun 27, 2018 according to StockzIntelligence. On Thursday, March 8 the firm has “Buy” rating by Roth Capital given. On Friday, June 1 the firm has “Buy” rating given by Maxim Group. On Friday, June 1 the company was maintained by H.C. Wainwright. On Monday, March 26 the rating was reinitiated by H.C. Wainwright with “Buy”.

For more Viking Therapeutics, Inc. (NASDAQ:VKTX) news posted recently go to: Fool.com, Fool.com, Fool.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Why Viking Therapeutics Stock Is On Fire Today” posted on May 31, 2018, “3 Growth Stocks at Deep-Value Prices” on June 15, 2018, “Viking Therapeutics, Buy the Dip?” with a publish date: June 26, 2018, “Viking Therapeutics: What Now After ‘Yuge’ Rally?” and the last “Viking Therapeutics: Sell The Pop On The Sympathy Play” with publication date: June 01, 2018.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.